Filtered By:
Management: Hospitals
Therapy: Statin Therapy
This page shows you your search results in order of relevance. This is page number 6.
Order by Relevance | Date
Total 100 results found since Jan 2013.
This Cholesterol Drug Combination Might Lower Your Risk of Death, Study Finds
(ORLANDO) — A newer cholesterol drug, used with older statin medicines, modestly lowered heart risks and deaths in a big study of heart attack survivors that might persuade insurers to cover the pricey treatment more often.
Results on the drug, Praluent, were announced Saturday at an American College of Cardiology conference in Florida. It’s the first time a cholesterol-lowering drug has reduced deaths since statins such as Lipitor and Crestor came out decades ago.
“It’s the ultimate outcome; it’s what matters to patients,” said study leader Dr. Philippe Gabriel Steg of Hospital Bichat i...
Source: TIME: Health - March 10, 2018 Category: Consumer Health News Authors: Marilyn Marchione / AP Tags: Uncategorized APH healthytime medicine onetime Source Type: news
Statins associated with improvement of rare lung disease
This study suggests that oral statin therapy may be a new approach for patients with autoimmune pulmonary alveolar proteinosis.AUTHORSThe study ’s co-senior authors are Dr. Elizabeth Tarling of UCLA and Dr. Bruce Trapnell of Children’s Hospital Medical Center of Cincinnati, Ohio. Other authors are listed in the journal article.JOURNALThe study was published in the journal Nature Communications. FUNDINGThe National Institutes of Health funded the research.Learn more about the cardiovascular research theme at UCLA.
Source: UCLA Newsroom: Health Sciences - August 17, 2018 Category: Universities & Medical Training Source Type: news
Fool Me Once: An Uncommon Presentation of PE
BY FREDDIE IRIZARRY-DELGADO; VAROON KAKAIYA; & AHMED RAZIUDDIN, MDAn 86-year-old African-American woman was brought to the ED by her daughter after two days of nutritional neglect, abdominal pain, and altered mental status. Her daughter said her mother felt lightheaded, appeared dehydrated, and vomited nonbilious watery fluid once. The patient had a history of diabetes mellitus type 2, DVT/PE, dementia, and early signs of parkinsonism.Her vital signs were remarkable only for tachypnea (24 bpm). Her troponin I was markedly elevated at 1.7 ng/mL. A D-dimer was ordered because of her history of unprovoked DVT/PE, and i...
Source: The Case Files - November 27, 2018 Category: Emergency Medicine Tags: Blog Posts Source Type: research
Half of patients on statins fail to reach ‘healthy’ cholesterol level after two years
Researchers say patients need tailored treatment to stave off heightened heart disease/stroke risk Related items fromOnMedica Ignored cholesterol blamed for heart attacks Polypill could halve cardiovascular events Oral anticoagulants after hospital discharge reduce non-fatal blood clots Hospitals fail women with myocardial infarction New class of chronic angina drug approved for use in Europe
Source: OnMedica Latest News - April 15, 2019 Category: UK Health Source Type: news
Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1
1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy
2Humanitas Clinical and Research Center-IRCCS, Milan, Italy
3Humanitas University, Milan, Italy
4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Publication date: Available online 1 July 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Kausik K Ray, Helen M Colhoun, Michael Szarek, Marie Baccara-Dinet, Deepak L Bhatt, Vera A Bittner, Andrzej J Budaj, Rafael Diaz, Shaun G Goodman, Corinne Hanotin, Robert A Harrington, J Wouter Jukema, Virginie Loizeau, Renato D Lopes, Angèle Moryusef, Jan Murin, Robert Pordy, Arsen D Ristic, Matthew T Roe, José TuñónSummaryBackgroundAfter acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4–1·8 mmol/L with ezetimibe or statins reduces...
Source: The Lancet Diabetes and Endocrinology - July 2, 2019 Category: Endocrinology Source Type: research
Impacts of Clinical Pharmacist Intervention on the Secondary Prevention of Coronary Heart Disease: A Randomized Controlled Clinical Study
This study aimed to investigate the impact of clinical pharmacist intervention on the prognosis of acute coronary syndrome (ACS) in Chinese patients with CHD. Two hundred and forty patients who had ACS were recruited. Participants were randomly assigned to the intervention group (n = 120) or the control group (n = 120). The intervention group received a medication assessment and education by the clinical pharmacist at discharge and telephone follow-ups at 1 week and 1 and 3 months after discharge. The control group received usual care. The primary outcomes of this study were the proportion of patients who had major adverse...
Source: Frontiers in Pharmacology - October 7, 2019 Category: Drugs & Pharmacology Source Type: research
Effect of high-dose strong statin for preventing periprocedural ischemic complications of carotid artery stenting
This study assessed the safety and usefulness of pretreatment using a high-dose strong statin (HDSS) to reduce the periprocedural ischemic complications of CAS. We analyzed 117 carotid lesions treated by CAS that were evaluated with magnetic resonance imaging (MRI) within 48 h after the procedure. For 67 lesions, an HDSS (rosuvastatin 20 mg or atorvastatin 40 mg daily) were prescribed from at least 14 days before CAS to at least 14 days after procedure (HDSS group). Clinical and angiographic data, as well as in-hospital outcomes, of the HDSS group were retrospecti vely compared with 50 lesions with conventional treat...
Source: Heart and Vessels - January 9, 2020 Category: Cardiology Source Type: research
Prevalence and predictors of statin utilization among patient populations at high vascular risk in Ghana
Inadequate implementation of evidence-based preventive measures for individuals at high risk of cardiovascular disease (CVD) will only worsen the current epidemic of CVDs in sub-Saharan Africa. We assessed rates and predictors of statin utilization among two high CVD risk patient populations, people with type 2 diabetes mellitus (T2DM) and those with stroke, encountered across five hospitals in Ghana.
Source: Journal of the Neurological Sciences - April 14, 2020 Category: Neurology Authors: Fred Stephen Sarfo, Bruce Ovbiagele Source Type: research
COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging Beyond Topics
AbstractCOVID 19 is much more than an infectious disease by SARS-CoV-2 followed by a disproportionate immune response. An older age, diabetes and history of cardiovascular disease, especially hypertension, but also chronic heart failure and coronary artery disease among others, are between the most important risk factors. In addition, during the hospitalization both hyperglycaemia and heart failure are frequent. Less frequent are acute coronary syndrome, arrhythmias and stroke. Accordingly, not all prolonged stays or even deaths are due directly to SARS-CoV-2. To our knowledge, this is the first review, focusing both on ca...
Source: The Journal of Nutrition, Health and Aging - May 11, 2020 Category: Nutrition Source Type: research
Impact of high-dose statin on cardiovascular outcomes in real-world patients with ST-elevation acute myocardial infarction
AbstractLittle is known about the impact of a high-dose statin on cardiovascular outcomes after ST-elevation acute myocardial infarction (STEMI) in real-world Japanese patients. Between July 2011 and June 2017, 1110 consecutive STEMI patients underwent primary percutaneous coronary intervention at our hospital and were discharged. A high-dose statin was administered in 117 patients (10.5%) and non-high-dose statin was administered in 947 patients (85.3%). The low-density lipoprotein cholesterol level was significantly higher in the high-dose statin group at admission (129.8 ± 44.9 vs. 110.4 ± 32.7,p < 0....
Source: Heart and Vessels - September 2, 2020 Category: Cardiology Source Type: research
Commentary: Untangling the Mystery of Statin Therapy in Treating Postoperative Atrial Fibrillation: Does the Underlying Cardiac Pathology Matter?
Atrial fibrillation (AF) is an important and common complication following cardiac surgery and is associated prolonged hospital stay, and increased perioperative and long term risk of stroke and mortality.1 Its adverse impact carries across all types of cardiac surgical procedures including surgical septal myectomy for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction.2 The cause of perioperative AF is incompletely understood, but pre-existing structural changes to the heart, particularly increased left atrial volume, sympathetic activation, and perioperative inflammation are considered important contributors.
Source: Seminars in Thoracic and Cardiovascular Surgery - February 15, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Francis D. Pagani Tags: ADULT – Commentary Source Type: research
Assistance and health care provided to adolescents with chronic and immunosuppressive conditions in a tertiary university hospital during the COVID-19 pandemic
The novel coronavirus disease (COVID-19) showed increased morbidity and mortality rates and worse prognosis in individuals with underlying chronic diseases, especially cardiovascular disease and its risk factors, such as hypertension, diabetes, and obesity. There is also evidence of possible links among COVID-19, myocardial infarction, and stroke. Emerging evidence suggests a pro-inflammatory milieu and hypercoagulable state in patients with this infection. Despite anticoagulation, a large proportion of patients requiring intensive care may develop life-threatening thrombotic complications. Indeed, the levels of some marke...
Source: Clinics - March 24, 2021 Category: General Medicine Source Type: research
About half of people living with HIV have coronary artery plaque despite low cardiac risk
(Massachusetts General Hospital) Higher levels of plaque in people with HIV can be partly traced to the nontraditional risk factors of increased arterial inflammation and immune system activation. Researchers uncovered two key biomarkers of plaque that will be studied in the next phase of the global REPRIEVE trial to predict coronary plaque progression and major cardiovascular events, such as heart attacks and stroke, and the potential effects of statins.
Source: EurekAlert! - Medicine and Health - July 6, 2021 Category: International Medicine & Public Health Source Type: news
Cancer-Associated Atherothrombosis: The Challenge
Int J Angiol DOI: 10.1055/s-0041-1729920The association between venous thrombosis and malignancy, having typical features of a paraneoplastic syndrome, has been established for a century. Currently, it is recognized that arterial thromboembolism (ATE) may also behave as a paraneoplastic syndrome. Recent matched cohort studies, systematic reviews, and observational studies concur in showing an increased incidence of acute coronary events, ischemic stroke, accelerated peripheral arterial disease, and in-stent thrombosis during the 6-month period before cancer diagnosis, peaking for 30 days immediately before cancer diagnosis...
Source: International Journal of Angiology - July 19, 2021 Category: Cardiology Authors: Naschitz, Jochanan E. Tags: Review Article Source Type: research
